Argenx shares fall after Vyvgart trial is scrapped
Argenx said it has scrapped a late-stage Vyvgart trial in Sjögren's disease after a data monitoring committee said it was likely to miss its primary endpoint. The stock fell 14% as the decision removed a key growth catalyst.